



Sarepta Therapeutics, Inc.

Ticker : SRPT

Country of Operation : USA

Meeting Date : 6/8/2023

Meeting Type : Annual

Item #	Proposal Text	Proponent	Mgmt Rec	Vote Instruction	Vote Rationale
1	Advisory Vote to Ratify Named Executive Officers' Compensation	Management	For	Against	Pay and performance are not adequately aligned for the period under review. Concern is noted around the extension of the vesting period for the CEOs front-loaded equity grants, which results in \$123 million in incremental value despite only up to 1/3rd of the award would have been earned under the original vesting schedule. Further, a substantial portion of LTI awards to other NEOs lack clear performance conditions.